Patients with pulmonary hypertension often have adverse outcomes after anesthesia. Tachycardia, hypertension, hypervolemia, increased intrathoracic pressure, acidosis, painful stimuli and hyperthermia are triggering factors for adverse perioperative events. Dexmedetomidine is a centrally acting α2 agonist which, due to its desirable properties like sympatholysis, bradycardia and μ agonism, can be a useful agent for patients with pulmonary hypertension. Dexmedetomidine also has the ability to potentiate inhalational, intravenous and regional anesthetics when it is used as an adjunct.